AMT-116 binds CD44v9 on tumor cells, is internalized, and releases a belotecan-derived TOP1 inhibitor (KL610023) that causes DNA damage and apoptosis. TOP1 is the intracellular payload target, not the antigen recognized for cell selection; thus TOP1 expression alone does not lead to targeted killing.